VVN461 / VivaVision - LARVOL DELTA

VVN461 Solution in Patients with Acute Noninfectious Anterior Uveitis. (PubMed, Ophthalmology) - No abstract available

Journal • Inflammation • Ocular Inflammation • Ophthalmology • Uveitis

A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis (clinicaltrials.gov) - P3 | N=152 | Not yet recruiting | Sponsor: VivaVision Biotech, Inc

New P3 trial • Ocular Inflammation • Ophthalmology • Uveitis

Double-Masked, Dose-Response, Vehicle-Controlled Study of VVN461 Ophthalmic Solution in Postoperative Ocular Inflammation. (PubMed, Ophthalmol Sci) - "In this double-masked, vehicle-controlled study, clinically and statistically significant anti-inflammatory efficacy was seen with few safety issues. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article."

Journal • Cataract • Inflammation • Ocular Inflammation • Ophthalmology

VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Non-Infectious Anterior Uveitis (PRNewswire) - P2 | N=89 | NCT06679153 | Sponsor: VivaVision Biotech, Inc | "VivaVision Biotech...today announced positive topline results from its phase 2 clinical trial of VVN461, a potent dual JAK1/TYK2 inhibitor for the treatment of Non-Infectious Anterior Uveitis (NIAU) in China....Subjects were randomized into three groups (VVN461-1.0%, VVN461-0.5%, and prednisolone acetate-1.0%) and received treatments for 28 days. Prednisolone acetate is the first-line corticosteroid therapy for NIAU. Both 0.5% and 1% of VVN461 ophthalmic solutions showed non-inferior efficacy compared to active control PA for its primary endpoint: subjects treated with VVN461 had 2 step decrease in ACC grade vs. subjects treated with prednisolone acetate (p <0.001). Note: ACC (anterior chamber cells) were evaluated using SUN grading scale....Full data will be reported in future publications in conferences and journals."

P2 data • Ophthalmology • Uveitis

Pharmacokinetics of VVN461 Ophthalmic Solution (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: VivaVision Biotech, Inc

New P1 trial • Ophthalmology

A phase 2, double-masked, randomized, vehicle-controlled study of VVN461 Ophthalmic Solution in treating post-operative ocular inflammation in subjects undergoing routine unilateral cataract surgery (ARVO 2025) - "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • P2 data • Surgery • Cataract • Ocular Inflammation • Ophthalmology • JAK1 • TYK2

Ocular pharmacokinetics and tolerability of VVN481, a novel JAK inhibitor, following suprachoroidal delivery in rabbits (ARVO 2025) - "VVN481, a prodrug of a highly potent and selective JAK1/TYK2 inhibitor VVN461, is formulated as a suspension for suprachoroidal injection using the Everads proprietary injector (Everads Therapy,Fig...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

PK/PD data • Preclinical • Age-related Macular Degeneration • Diabetic Retinopathy • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders • Uveitis • JAK1 • TYK2

High ocular and low systemic exposure of topical VVN461, a First-in-class Topical JAK inhibitor targeting ocular inflammation (ARVO 2025) - "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Cataract • Ocular Inflammation • Ophthalmology • Uveitis • JAK1 • TYK2

A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis (clinicaltrials.gov) - P2 | N=89 | Completed | Sponsor: VivaVision Biotech, Inc | Terminated ➔ Completed

Trial completion • Ocular Inflammation • Ophthalmology • Uveitis

A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis (clinicaltrials.gov) - P2 | N=89 | Terminated | Sponsor: VivaVision Biotech, Inc | Trial completion date: Mar 2025 ➔ Dec 2024 | Recruiting ➔ Terminated | Trial primary completion date: Mar 2025 ➔ Dec 2024

Trial completion date • Trial primary completion date • Trial termination • Ocular Inflammation • Ophthalmology • Uveitis

A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: VivaVision Biotech, Inc

New P2 trial • Ocular Inflammation • Ophthalmology • Uveitis

Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery (clinicaltrials.gov) - P2 | N=91 | Completed | Sponsor: VivaVision Biotech, Inc | Recruiting ➔ Completed | Trial completion date: Dec 2024 ➔ May 2024 | Trial primary completion date: Dec 2024 ➔ May 2024

Surgery • Trial completion • Trial completion date • Trial primary completion date • Cataract • Inflammation • Ocular Inflammation • Ophthalmology

Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery (clinicaltrials.gov) - P2 | N=90 | Recruiting | Sponsor: VivaVision Biotech, Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Cataract • Inflammation • Ocular Inflammation • Ophthalmology

Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery (clinicaltrials.gov) - P2 | N=90 | Not yet recruiting | Sponsor: VivaVision Biotech, Inc

New P2 trial • Cataract • Inflammation • Ocular Inflammation • Ophthalmology